Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.76 |
| ▸ | DRD2 | P14416 | 2/20 | 0.76 |
| ▸ | HTR2A | P28223 | 2/20 | 0.76 |
| ▸ | HTR2C | P28335 | 2/20 | 0.76 |
| ▸ | HTR2B | P41595 | 2/20 | 0.76 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7358604 | 0.87 | SIGMAR1 (0.74) | SIGMAR1DRD2HTR2AHTR2CHTR2B | |
| SCHEMBL7363419 | 0.87 | SIGMAR1 (0.74) | SIGMAR1DRD2HTR2AHTR2CHTR2B | |
| SCHEMBL7358803 | 0.87 | SIGMAR1 (1.00) | SIGMAR1DRD2HTR2AHTR2CHTR2B | |
| Bromide SCHEMBL467156 | 0.85 | SIGMAR1 (1.00) | SIGMAR1DRD2HTR2AHTR2CHTR2B | |
| SCHEMBL17141124 | 0.85 | SIGMAR1 (0.53) | SIGMAR1DRD2HTR2AHTR2CHTR2B | |
| SCHEMBL7357328 | 0.83 | SIGMAR1 (1.00) | SIGMAR1DRD2HTR2AHTR2CHTR2B | |
| SCHEMBL7378521 | 0.80 | BCHE (0.64) | — | |
| SCHEMBL6691292 | 0.79 | PDE4A (0.50) | SIGMAR1DRD2HTR2AHTR2CHTR2B | |
| SCHEMBL6692054 | 0.77 | PDE4A (0.52) | SIGMAR1DRD2HTR2AHTR2CHTR2B | |
| Fumaric Acid SCHEMBL466968 | 0.77 | SIGMAR1 (0.86) | SIGMAR1DRD2HTR2AHTR2CHTR2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5296479-A | Treating physiological or drug-induced psychosis or dyskinesia | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1994-03-22 | — | — | US | disclosed |
| US-5266572-A | Antipsychotic 1-cycloalkylpiperidines | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1993-11-30 | — | — | US | disclosed |
| US-5243048-A | Treatment of drug-induced or physiological psychosis or dyskinesia; side effect reduction | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1993-09-07 | — | — | US | disclosed |
| EP-0490962-A1 | ANTIPSYCHOTIC 1-CYCLOALKYLPIPERIDINES | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1992-06-24 | — | — | EP | disclosed |
| US-5109002-A | ANTIPSYCHOTIC 1-CYCLOALKYLPIPERIDINES | DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1992-04-28 | — | — | US | disclosed |
| WO-1991003243-A1 | ANTIPSYCHOTIC 1-CYCLOALKYLPIPERIDINES | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1991-03-21 | — | — | WO | disclosed |